Presentation Authors: Thorsten Bach*, Hamburg, Germany, Iannis Giannakis, Frauenfeld, Switzerland, Magdalena Karimi, Hamburg, Germany, Enrique Rijo, Barcelona, Spain
Introduction: Aquablation offers autonomous tissue removal for the treatment of BPO and showed effective symptom relief and reduced risk of sexual dysfunction compared to TURP in a RCT. The aim of this study was to evaluate the efficacy of Aquablation in a non-selected consecutive cohort of patients within daily routine.
Methods: In this prospective single-centre data collection, all patients undergoing Aquablation therapy have been evaluated for perioperative course, morbidity and symptom relief after 3 and 6 months.
Results: 180 consecutive patients have been included in this prospective trial. Mean prostate volume was 69.7cc and decreased to 22.7cc after 3 months, mean age was 69.4y. 26.7% of the patients have been on catheter due to retention prior to surgery. OR-time (TRUS-Foley) was 18.7 min in the mean, Aquablation time was 3.5 min, including 26 patients with >1 Aquablation passage due to prostate volume or configuration. Mean haemoglobin drop was 1.84 points, however, 8 patients (4.4%) needed transfusion of RBC. Secondary cautery due to delayed bleeding was necessary in 7 patients (3.9%). IPSS (21 (preop.) vs. 7 (3month) vs. 5.9 (6 month)); QoL (4.6 vs. 1.6 vs. 1.4); Qmax (11.4 ml/s (preop) vs. 20.1 ml/s (3 month)); PVR (187.8 ml (preop.) vs. 15 ml (3 month)) decreased significantly in the postoperative course. Antegrade ejaculation was preserved in 63% of the cases and 89% of the patients stated that based on their experience they would undergo the same surgery again.
Conclusions: Aquablation is safe and effective in a real-life setting in a non-selected patient cohort. Although still in an early phase of clinical implementation, the presented results of this largest single-center cohort emphasize the future potential of this new treatment modality for BPO.